Six models, built by different teams, all read the treated patients as younger.

Insilico Medicine's AI-discovered drug rentosertib enters Phase III trials for lung fibrosis, targeting cellular senescence with implications for

Six proteomic ageing clocks agreed patients on Insilico’s AI-designed lung drug looked younger. The authors cannot yet rule out the treated lung.